JPL934™
Clinically Proven
Probiotics Blend
Clinically Proven Probiotics Blend which can improve bowel movement, gut health, and lower gastrointestinal symptoms.
Lactobacillus johnsonii IDCC 9203
Lactobacillus plantarum IDCC 3501
Bifidobacterium lactis IDCC 4301
Human Clinical Test Details of JPL934™
Improvement in Overall
Symptoms at Week 8
A significantly higher relief of overall lower abdominal symptoms was observed in the ID-JPL934 group than in the placebo group in the intention-to-treat analysis. This result was also significant in per-protocol analysis.
Relief of overall symptoms in the ID-JPL934 group vs. placebo group after 8-week treatment.
Changes in
Lower Abdominal Symptoms
A comparison of the two groups for changes in stool form, stool frequency, and abnormal bowel movement symptoms from baseline to week 8 revealed a higher decrease in abdominal pain and bloating in the ID-JPL934 group than in the placebo group, suggesting significant differences between the two groups.
Comparison of changes in stool form, frequency of bowel movements per day, and abnormal bowel movement symptoms from baseline to week 8 between the 2 groups.
Metagenomic analysis of
participants’ fecal samples.
The levels of serum IL-6 were significantly decreased in the ID-JPL934 group after the treatment, while no significant changes were found in the levels of the placebo group, and the difference was significant.
Effects of ID-JPL934 on blood levels of IL-6
Analysis of quantitative changes
in probiotic levels of feces
Higher levels of species-specific sequences associated with probiotic formulations were detected in the fecal DNAs of subjects treated with ID-JPL934 than in those in the placebo group, based on quantitative polymerase chain reaction (qPCR) results.
Quantitative changes in fecal probiotic levels at baseline and at week 8.